Business · 27/01/2026Updated: 10/16/2026 · 1 min read
FDA Determines Regulatory Review Period for EXBLIFEP Patent Extension
Summary
The FDA has determined the regulatory review period for EXBLIFEP, a human drug product, due to patent extension applications submitted to the USPTO, as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →